Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.

Purpose: Lipid and transaminase levels after conversion from immediate-release niacin to extended-release niacin were evaluated.

Methods: All patients who had their medications converted from Niaspan to Slo-Niacin between March 2008 and January 2009 were considered for evaluation. Subjects who took =2000 mg of Niaspan were automatically converted to Slo-Niacin in a 1:1 dosing ratio conversion.